- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
19 result(s) found for: Aortic Root.
Displaying page 1 of 1.
EudraCT Number: 2010-018880-41 | Sponsor Protocol Number: CARDPED-2010-01 | Start Date*: 2010-06-01 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: EFFECTS OF LOSARTAN ON AORTIC ROOT AND ASCENDING AORTA REMODELING IN PATIENTS WITH BICUSPID AORTIC VALVE. | |||||||||||||
Medical condition: PATIENTS WITH BICUSPID AORTIC VALVE. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000513-14 | Sponsor Protocol Number: NBK154/2/2021 | Start Date*: 2023-03-08 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-b... | ||
Medical condition: Marfan Syndrome Diseases related to Marfan syndrome (rare diseases with aneurysms of the thoracic aorta and dissection of the aorta), among others: Loeys-Dietz syndrome, Vascular type of Ehlers-Da... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001462-81 | Sponsor Protocol Number: FARM7KP2PX | Start Date*: 2008-10-27 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations | |||||||||||||
Medical condition: Marfan Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019302-16 | Sponsor Protocol Number: 2010GU001B | Start Date*: 2010-09-13 |
Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust | ||
Full Title: A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome | ||
Medical condition: Marfan Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004778-99 | Sponsor Protocol Number: 120895 | Start Date*: 2005-06-14 |
Sponsor Name:Pediatric Unit, Hillerød Hospital | ||
Full Title: The growth of the internal genitalia and the bone mineralization during hormonal replacement therapy and the presence of aortic root dilatation in girls with Turner Syndrome | ||
Medical condition: Turner Syndrome is a common chromosomal abnormalities, characterized by one X-chromosome or a partial deletion in all or some cell-lines. The syndrome is known for features as short stature and abs... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023612-14 | Sponsor Protocol Number: N/A | Start Date*: 2013-03-08 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso... | |||||||||||||
Medical condition: Marfan syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006968-11 | Sponsor Protocol Number: AP214-CS005 | Start Date*: 2009-04-21 | |||||||||||
Sponsor Name:Action Pharma A/S | |||||||||||||
Full Title: Pharmacokinectics of AP214 Acetate in patients undergoing cardiac surgery. A randomized, double-blind, placebo-controlled sequential ascending dose trial investigating pharmacokinetics, as well as... | |||||||||||||
Medical condition: Action Pharma A/S is developing AP214 Acetate for the prevention of postsurgical kidney injury after thoracic aortic aneurysm repair surgery. In phase 2: Patients undergoing cardiac surgery, defin... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005862-10 | Sponsor Protocol Number: AGO/2007/011 | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | |||||||||||||
Medical condition: Marfan syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001808-57 | Sponsor Protocol Number: BICATOR | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Assessment of atorvastatin efficacy on the progression of aortic dilatation and valvular degeneration in patients with bicuspid aortic valve (BICATOR) | |||||||||||||
Medical condition: Valve Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003991-37 | Sponsor Protocol Number: AGO/2006/009 | Start Date*: 2006-12-13 | |||||||||||
Sponsor Name:University Hospital Gent | |||||||||||||
Full Title: Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome | |||||||||||||
Medical condition: Marfan syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016139-36 | Sponsor Protocol Number: V1,11.05.2009 | Start Date*: 2009-12-28 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Kinder-und Jugendheilkunde | ||
Full Title: The AT1 receptor antagonist losartan for the prevention of excessive aortic root dilatation in children and adolescents with Marfan syndrom | ||
Medical condition: Marfan-Syndrom | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003942-33 | Sponsor Protocol Number: M13-796 | Start Date*: 2013-05-03 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk... | |||||||||||||
Medical condition: Acute Kidney Injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022630-92 | Sponsor Protocol Number: AP214-CS007 | Start Date*: 2010-11-05 | |||||||||||
Sponsor Name:Action Pharma A/S | |||||||||||||
Full Title: An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Su... | |||||||||||||
Medical condition: Action Pharma is developing AP214 Acetate for the prevention of postsurgical kidney injury after cardiac surgery. Trial population is patients with increased risk for development of Kidney Inju... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003113-15 | Sponsor Protocol Number: QRK209 | Start Date*: 2016-08-02 | |||||||||||
Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI following Ca... | |||||||||||||
Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002556-27 | Sponsor Protocol Number: ALBICS | Start Date*: 2016-11-25 | |||||||||||
Sponsor Name:Helsinki University Hospital | |||||||||||||
Full Title: Albumin in cardiac surgery | |||||||||||||
Medical condition: Cardiac surgery with cardiopulmonary bypass operations. Elective and emergency patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003883-30 | Sponsor Protocol Number: 044CF13273 | Start Date*: 2014-01-30 | |||||||||||
Sponsor Name:Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A | |||||||||||||
Full Title: Efficacy and safety of paracetamol in comparison to ibuprofen for patent ductus arteriosus treatment in preterm infants. A randomized, open label, comparator-controlled, prospective study. | |||||||||||||
Medical condition: Patent ductus arteriosus | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000757-49 | Sponsor Protocol Number: QRK309 | Start Date*: 2018-12-05 | |||||||||||
Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for A... | |||||||||||||
Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018086-12 | Sponsor Protocol Number: BI1412_2009 | Start Date*: 2010-08-23 | ||||||||||||||||||||||||||
Sponsor Name:Athena Care/ Isala Klinieken | ||||||||||||||||||||||||||||
Full Title: Efficacy and safety of Haemocomplettan® P in patients experiencing microvascular bleeding while undergoing elective complex cardiac surgery | ||||||||||||||||||||||||||||
Medical condition: Elective complex cardiac surgery is associated with excessive blood loss due to coagulopathy. Fibrinogen concentrate has been shown to reverse dilutional coagulopathy. In this double blinded, place... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011279-56 | Sponsor Protocol Number: IBU/20mg/2009 | Start Date*: 2009-07-31 | |||||||||||
Sponsor Name:Orphan Europe Recordati | |||||||||||||
Full Title: Multicenter open-label pilot study to evaluate the safety, pharmacology and efficacy of a new dose regimen (i.e. 20-10-10 mg/kg) of Pedea (intravenous ibuprofen) in preterm newborn infants of less ... | |||||||||||||
Medical condition: Hemodynamically significant persisting ductus arteriosus in preterm infants of less than 28 weeks of gestational age | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.